argenx SE (NASDAQ:ARGX) Surpasses Earnings and Revenue Estimates

Core Insights - Argenx SE (ARGX) is a global leader in immunology, focusing on innovative therapies for severe autoimmune diseases, competing with firms like Alexion Pharmaceuticals and Horizon Therapeutics [1] Financial Performance - On October 30, 2025, ARGX reported earnings per share of $4.40, surpassing the estimated $4.37 [2][6] - The company achieved revenue of approximately $1.12 billion, exceeding the estimated $1.07 billion [2][6] - Global product net sales for the third quarter of 2025 reached $1.13 billion [2] Pipeline and Development - Argenx is set to submit a supplemental Biologics License Application (sBLA) for seronegative generalized myasthenia gravis (gMG) by the end of the year [3] - The company plans to report results from the ADAPT-OCULUS study in the first half of 2026, aiming for the broadest myasthenia gravis label of any biologic [3] - Five registrational study readouts are anticipated in 2026 from its leading immunology pipeline [4] Growth Strategy - The expansion of VYVGART in two blockbuster indications and the advancement of five registrational programs demonstrate the company's growth strategy [4] - The management will host a conference call to discuss updates, reflecting proactive communication with stakeholders [4] Financial Ratios - ARGX has a price-to-earnings (P/E) ratio of approximately 36.57, indicating investor confidence [5] - The price-to-sales ratio is about 13.74, and the enterprise value to sales ratio is around 13.19, reflecting strong market valuation [5] - The company maintains a strong financial position with a debt-to-equity ratio of 0.007 and a current ratio of approximately 5.60 [5]